Are you a candidate for ChondroFiller injection?

ChondroFiller injection is designed for a specific clinical picture, not shoulder pain in general. The procedure is suited to adults with MRI-confirmed focal chondral defects graded Outerbridge III or IV in the glenohumeral joint — meaning the cartilage is significantly thinned or absent across a defined area, but the surrounding cartilage and the subchondral bone beneath it remain structurally sound. Defect size is typically up to approximately 3 cm², though the injection route can be considered for lesions extending to 6 cm² in appropriate cases.

One practical advantage over surgical cartilage procedures is the absence of an upper age limit. Because ChondroFiller injection relies on the body's own progenitor cells migrating into the scaffold rather than requiring large volumes of new cartilage growth, it is not restricted by the age thresholds that apply to cell-based surgical techniques.

Candidacy is also defined by what rules a patient out. Widespread glenohumeral osteoarthritis is a clear exclusion — where joint degeneration is diffuse rather than focal, injectable scaffold repair is unlikely to deliver meaningful benefit. Proxy evidence from hip arthroscopy series shows that patients with advanced pre-existing OA (Tönnis grade 2–3) achieve consistently poor outcomes, and the same principle applies to the shoulder. Active joint infection, untreated ligamentous instability, and known allergy to collagen or rat-derived proteins are additional contraindications.

Whether a specific shoulder presentation meets these criteria cannot be determined from imaging alone. A specialist assessment — including a structured review of MRI findings and joint stability — is the necessary first step.

How ChondroFiller injection rebuilds shoulder cartilage

The product itself contains no living cells and no harvested donor material — just an ultrapure, murine-derived Type I collagen solution supplied in a ready-to-use dual-chamber syringe. When the two chambers mix on delivery, the result is a viscous liquid that can be guided precisely into the glenohumeral joint under ultrasound. Once inside, it self-gels in approximately three to five minutes, forming a dimensionally stable hydrogel scaffold that fills and conforms to the defect.

What happens next is the key distinction from older marrow-stimulation approaches such as microfracture. There is no drilling through the subchondral bone, no fibrin glue, and no requirement to introduce cells from an external source. Instead, the scaffold functions as a chemotactic matrix — a structural invitation, in effect — that signals the body's own progenitor cells to migrate in from the adjacent synovium and subchondral bone. Once recruited, those cells are guided by the collagen environment to differentiate into chondrocytes, the specialised cells responsible for producing cartilage tissue. This process is termed acellular matrix-induced chondrogenesis.

For the shoulder, one anatomical factor deserves honest acknowledgement. The glenohumeral joint's shallow glenoid fossa — often likened to a golf ball resting on a tee — generates multi-directional mechanical forces on any deposited scaffold that are less predictable than the more constrained loading environment of the knee or hip. This does not exclude the shoulder as an indication, but it is a genuine clinical nuance that informs patient selection and realistic outcome expectations.

What to expect at your ChondroFiller appointment

From the moment a patient arrives to the moment they leave, the appointment runs to approximately one hour — with no theatre admission, no surgical incision, and no general anaesthetic required at any stage.

The session follows a defined sequence. It opens with an imaging review: the treating clinician works through the patient's MRI to confirm the exact location, dimensions, and boundaries of the cartilage defect. This informs the defect mapping that determines precisely how the scaffold will be positioned.

The injection is then delivered under real-time ultrasound guidance. Unlike fluoroscopic techniques, ultrasound produces no ionising radiation, and it allows the clinician to visualise the needle entering the glenohumeral joint space and confirm accurate placement at the moment of delivery. The patient remains awake throughout.

No preparation of the scaffold is required in the room. The product arrives in a ready-to-use dual-chamber syringe; the collagen solution and its neutralisation agent mix automatically through an adapter the moment delivery begins, then gel in situ once inside the joint. The clinical team does not need to mix, prepare, or activate the material separately.

Before leaving, patients receive intravenous antibiotic cover as a precautionary measure. A six-week follow-up appointment is then arranged before discharge — the point at which the initial phase of scaffold integration is typically reviewed.

Realistic outcomes and the evidence behind them

Published data across knee, hip, and mixed-joint cohorts shows that 70–85% of patients treated with ChondroFiller injection achieve meaningful symptom relief at three to five years. That figure is a reasonable starting point for expectation-setting, but it requires an important qualification: no shoulder-specific randomised controlled trial data currently exists for ChondroFiller. The entire efficacy evidence base is drawn from other joints, and patients deserve to know that plainly before proceeding.

Extrapolation to the shoulder is scientifically grounded — the mechanism of acellular matrix-induced chondrogenesis is not joint-specific, and the glenohumeral joint is an explicitly listed indication in the device's CE certification — but it remains extrapolation. As noted in the preceding section, the multi-directional loading environment of the shoulder's shallow glenoid fossa is less predictable than the knee or hip, and whether scaffold durability matches what knee and hip cohorts have shown is a question that shoulder-specific follow-up data have yet to fully answer.

The appropriate frame is therefore: a strong mechanistic rationale, promising cross-joint outcomes, and shoulder-specific evidence that is still emerging. Many patients may achieve substantial and lasting relief; some may experience a more limited or shorter-lived response. No injection-based scaffold procedure should be framed as a guaranteed cure.

What the procedure is designed to do is preserve the joint — to slow or halt cartilage deterioration in a way that delays, and may help avoid, total shoulder replacement. Recovery trajectory and rehabilitation expectations are individual and best discussed at the clinical assessment, where defect size, joint condition, and activity goals can all be weighed together.

ChondroFiller injection versus surgical cartilage repair

The choice between ChondroFiller injection and surgical cartilage repair turns on three practical axes: where treatment is delivered, how many stages it involves, and who qualifies.

Setting

ChondroFiller injection is an ultrasound-guided outpatient procedure with no theatre booking, no general anaesthetic, and no surgical incision. Surgical alternatives sit in a different category entirely. Liquid Cartilage™ — the keyhole cartilage regeneration procedure offered by the same clinical group — is performed under general anaesthetic in theatre at approximately £9,800, reserved for contained focal lesions that meet arthroscopic criteria. Microfracture and ACI similarly require theatre admission and anaesthesia.

Staging

ChondroFiller injection is single-stage. ACI and MACI both involve two separate procedures: a biopsy to harvest chondrocytes, a period of cell culture, and a later re-implantation. For patients seeking to minimise procedural steps and recovery episodes, single-stage options carry a meaningful practical advantage.

Eligibility

The injection route carries no upper age limit and no fixed defect-size ceiling — a broader reach than several surgical options. OATS and MACI require harvesting donor tissue from elsewhere in the joint, which introduces donor-site considerations that do not apply to an injectable scaffold.

None of this makes ChondroFiller injection universally the right choice. Patients with widespread glenohumeral osteoarthritis fall outside scope for any cartilage-repair pathway; the relevant conversation for that group moves toward joint preservation or replacement. Which approach suits a specific defect, patient profile, and activity level is a matter for clinical assessment rather than a checklist comparison.

Cost, access, and booking an assessment

ChondroFiller injection is available in the UK through self-funded private care only — it is not NHS-commissioned and is not covered by standard private medical insurance policies. Patients should plan accordingly before requesting an assessment.

Pricing at London Cartilage Clinic is all-inclusive, covering imaging review, the ultrasound-guided injection, intravenous antibiotic cover, and the six-week follow-up appointment. The cost ranges from £3,000 for a single box to £5,500 for two boxes and £8,000 for three; the number of boxes required depends on the size and location of the defect and is determined at assessment. Most patients are treated with a single box.

London Cartilage Clinic on Harley Street was the first UK clinic to offer ChondroFiller as an ultrasound-guided outpatient injection, led by Professor Paul Y. F. Lee. The pathway begins with an MRI review and specialist consultation to confirm whether the defect and joint condition make the procedure suitable before any treatment is planned.

Patients wishing to explore whether they are candidates can book an initial consultation at londoncartilage.com.